141 results on '"Jouenne, Fanélie"'
Search Results
2. Re-evaluation of the concept of basaloid follicular hamartoma associated with naevoid basal cell carcinoma syndrome: a morphological, immunohistochemical and molecular study
3. Pulmonary Langerhans cell histiocytosis – an update on pathogenesis and treatment
4. Porocarcinomas with PAK1/2/3 fusions: a series of 12 cases.
5. Macrophage-derived CXCL9 and CXCL11, T-cell skin homing, and disease control in mogamulizumab-treated CTCL patients
6. Clinicopathologic and molecular characterization of melanomas mutated for CTNNB1 and MAPK
7. Genomic profiling of a skin adnexal carcinomas cohort using a comprehensive high throughput sequencing approach
8. The key role of oncopharmacology in therapeutic management, from common to rare cancers: A literature review
9. Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mutated Melanoma
10. Erratum to ‘Molecular profiling of anal Paget’s disease and underlying anal adenocarcinoma highlights their common origin’ [EJC Skin Cancer 1 (2023) 100002]
11. A Melanoma-Tailored Next-Generation Sequencing Panel Coupled with a Comprehensive Analysis to Improve Routine Melanoma Genotyping
12. Combined PDE4+MEK inhibition shows antiproliferative effects in NRASQ61 mutated melanoma preclinical models.
13. Combined PDE4+MEK inhibition shows antiproliferative effects in NRAS Q61 mutated melanoma preclinical models
14. Mitogen-activating protein kinase pathway alterations in Langerhans cell histiocytosis
15. TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro
16. Paraneoplastic pemphigus uncovers distinct clinical and biological phenotypes of western unicentric Castleman disease
17. Recurrent PAK2 rearrangements in poroma with folliculo‐sebaceous differentiation
18. Management and outcomes of pneumothorax in adult patients with Langerhans cell Histiocytosis
19. Supplementary Tables from Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAFV600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism
20. Molecular profiling of anal Paget’s disease and underlying anal adenocarcinoma highlights their common origin
21. Chapitre 8 - Traitements médicamenteux du cancer
22. Eruptive squamous cell carcinomas following an acute skin inflammatory disease: A series of four cases
23. Germline CDKN2A/P16INK4A mutations contribute to genetic determinism of sarcoma
24. The MAPK Pathway in Pulmonary Langerhans Cell Histiocytosis
25. Carcinomes épidermoïdes éruptifs dans un contexte de dermatose inflammatoire aiguë : une série de 4 cas
26. Macrophage-derived CXCL9 and CXCL11 recruit CD8 T cells in skin and provide long-term disease control in mogamulizumab-treated CTCL patients
27. Clinicopathologic and molecular characterization of melanomas mutated for CTNNB1 and MAPK
28. The PI3K/mTOR Pathway Is Targeted by Rare Germline Variants in Patients with Both Melanoma and Renal Cell Carcinoma
29. Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAFV600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism
30. The MAPK Pathway in Pulmonary Langerhans Cell Histiocytosis
31. Custom pyrosequencing assay to detect short BRAF deletions in Langerhans cell histiocytic lesions
32. Conservative management is effective in unicystic ameloblastoma occurring from the neonatal period: A case report and a literature review
33. Lack of evidence for the involvement of Merkel cell polyomavirus in pulmonary Langerhans cell histiocytosis
34. Development and validation of a liquid chromatography tandem mass spectrometry quantification method for 14 cytotoxic drugs in environmental samples
35. Impact of Raltegravir or Efavirenz on Cell-Associated Human Immunodeficiency Virus-1 (HIV-1) Deoxyribonucleic Acid and Systemic Inflammation in HIV-1/Tuberculosis Coinfected Adults Initiating Antiretroviral Therapy
36. Eruptive squamous cell carcinomas following an acute skin inflammatory disease: A series of four cases.
37. Custom pyrosequencing assay to detect short BRAF deletions in Langerhans cell histiocytic lesions.
38. Genetic landscape of adult Langerhans cell histiocytosis with lung involvement
39. Clinical impact of BRAFV600E mutation in adult pulmonary Langerhans cell histiocytosis
40. Atypical BRAF and NRAS Mutations in Mucosal Melanoma
41. Discoidin domain receptors: A promising target in melanoma
42. Tre-O2-05 - Macrophage-derived CXCL9 and CXCL11 recruit CD8 T cells in skin and provide long-term disease control in mogamulizumab-treated CTCL patients
43. Mitogen-activating protein kinase pathway alterations in Langerhans cell histiocytosis.
44. Constitutional Exome Sequencing contribution for identification of new cancer predisposing genes, sarcoma and pediatric melanoma
45. Melanoma Risk and Melanocyte Biology.
46. Genetic landscape of pulmonary langerhans cell histiocytosis
47. Pneumothorax in pulmonary langerhans cell histiocytosis (PLCH)
48. Germline CDKN2A/P16INK4A mutations contribute to genetic determinism of sarcoma.
49. Custom pyrosequencing assay to detect short BRAFdeletions in Langerhans cell histiocytic lesions
50. GermlineCDKN2A/P16INK4A mutations contribute to genetic determinism of sarcoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.